Clinical trials: Advanced Age
Influenza
Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate
The purpose of this study is to evaluate the immunogenicity and the safety of the candidate vaccine compared to Fluarix™ administered intramuscularly in elderly aged 60 years and above
- Trial name
- NCT00363077
- Testing
- GSK1247446A Group, Fluarix™
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cancer Pain
Unique Treatment of Oncology Pain in Advanced Cancer
This will be a proof-of-concept, single arm study with a maximum of 20 patients to evaluate preliminary analgesic efficacy and safety of Trichomylin® in patients with advanced cancer (male and female) who suffer from moderate to…
- Trial name
- UTOPIA-1 (NCT06533657)
- Testing
- Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- ZYUS Life Sciences Inc.
Depressive Disorder, Major
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive…
- Trial name
- NCT04513912
- Testing
- Seltorexant, Quetiapine XR
- Where
- 175 sites in United States, Argentina and 13 more
- Volunteers
- 757 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease, Dementia
ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE
In 1906, Dr. Alois Alzheimer first described the disease that later took his name. Today, 100 years later, 24 million people worldwide suffer from Alzheimer's disease or other dementias.
- Conditions
- Alzheimer Disease, Dementia, Cognitive Disorders
- Trial name
- ADVANCE (NCT01772095)
- Where
- Greece
- Volunteers
- 389 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Sarcopenia
Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly
The primary objective of this trial is to evaluate the effect of oral administration of an Astaxanthin formulation compared to placebo after one month alone and after an additional 3 months of exercise training on mitochondrial…
- Trial name
- NCT03368872
- Testing
- Astaxanthin formulation, Exercise training
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Astavita, Inc.
Diabetes, Healthy
Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers
This trial is conducted in Europe. The aim of this trial is to compare the exposure of liraglutide in young versus elderly healthy subjects.
- Trial name
- NCT01507337
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
CNS
2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects
This is a single-center, randomized, double-blind, placebo-controlled, sequential, multiple-dose study. The study will be conducted in two parts: Part A (6 cohorts of healthy adults receiving evening dosing) and Part B (one…
- Trial name
- NCT01673451
- Testing
- E2006
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Sarcopenia in Elderly, Malnourished
The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population
Examining the effects of MediDrink Platinum+ containing novel protein blend SRP-01 alone or when combined with PeptiStrong on clinical responses in elderly adults with sarcopenia
- Conditions
- Sarcopenia in Elderly, Malnourished, Protein Supplementation, Muscle Mass
- Trial name
- NCT07322653
- Testing
- MediDrink Platinum+, MediDrink Platinum+ and PeptiStrong
- Where
- 2 sites in Hungary
- Volunteers
- 75 people
- Sponsor
- Nuritas Ltd
Multiple Myeloma
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
This is a single center study to assess the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma in China.
- Trial name
- NCT04537442
- Testing
- IM21 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Nocturia, Benign Prostatic Hypertrophy (BPH)
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
The purpose of this study is to establish the dose response relationship of VA106483 and nocturnal urine volumes in a population of elderly male subjects with Benign Prostatic Hypertrophy (BPH) who are likely to present with…
- Trial name
- NCT01330927
- Testing
- VA106483
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Vantia Ltd
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
The study aim is to compare safety and efficacy of high-dose lenalidomide regimen, sequential azacitidine and lenalidomide and an azacitidine in persons ≥65 years with newly-diagnosed acute myeloid leukemia (AML).
- Trial name
- NCT01358734
- Testing
- Azacitidine, Lenalidomide, Best Supportive Care (BSC)
- Where
- 30 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Celgene
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV…
- Trial name
- NCT06389487
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 52 sites in United States, Australia and 4 more
- Volunteers
- 1,459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypertension
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.
- Trial name
- NCT00706134
- Testing
- Aliskiren 75 mg, Aliskiren 150 mg, Aliskiren 300 mg
- Where
- 8 sites in Argentina, Czechia and 6 more
- Volunteers
- 756 people
- Sponsor
- Novartis
Incontinence-associated Dermatitis
How Wet Pads Affect Elderly Skin: Measuring Changes in the Skin Barrier
The main aim of this study is to describe the effects of dry or wet incontinence pad material on the skin barrier function by measuring the changes of the stratum corneum on healthy participants due to the application of pads…
- Trial name
- DROPBOX (NCT07164898)
- Testing
- Test patches
- Where
- Sweden
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Essity Hygiene and Health AB
Cognition
Acute Effects of Supplemental Oxygen on Memory Testing in Healthy Adult Volunteers
Forty healthy adults (i.e., not recruited with respect to any particular diagnosis) are each alternately provided with supplemental oxygen and air via nasal cannula at about 6 Liters per Minute (LPM), while completing memory…
- Trial name
- NCT06555484
- Testing
- Cross Over Assignment Supplemental Oxygen and Supplemental Air
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Inogen Inc.
COVID-19
A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers
This is a phase II, observer-blind, multiple-centre, randomized, placebo-controlled study to evaluate the immunogenicity, safety, tolerability and lot consistency of 2 doses of UB-612 vaccine in adolescent, younger and elderly…
- Trial name
- NCT04773067
- Testing
- UB-612
- Where
- 12 sites in Taiwan
- Volunteers
- 3,877 people, healthy volunteers welcome
- Sponsor
- United Biomedical Inc., Asia
Leukemia, Neoplasms
Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known
The present trial will be performed according to an open design to determine the maximum tolerable dose (MTD) by evaluation of dose-limiting toxicity (DLT) of volasertib in paediatric leukaemia and solid tumours in the age group…
- Trial name
- NCT01971476
- Testing
- volasertib
- Where
- 5 sites in Belgium, Czechia and 3 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Frailty, Muscle Loss
A Randomized-Control Study of Gym Tonic's Community Based Strength Training Intervention.
Launched in April 2015 , Gym Tonic is the first of its kind cross-border exercise-as-medicine partnership between research institutions, business enterprises and service providers from Singapore and Finland.
- Conditions
- Frailty, Muscle Loss, Sarcopenia
- Trial name
- NCT04661618
- Testing
- Gym Tonic programme and Gym equipment
- Where
- Singapore
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- PulseSync Pte Ltd
Alzheimer's Disease
Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147
This Phase I clinical study is a randomized, double-blind, placebo-controlled, parallel-design study to thoroughly assess the safety profile and PK properties of J147 in healthy subjects.
- Trial name
- NCT03838185
- Testing
- J147
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Abrexa Pharmaceuticals, Inc.
Respiratory Syncytial Virus Infections
Safety and Efficacy of BARS13 in the Elderly
Advaccine Clinical Research are developing a vaccine called BARS13 for the active immunisation of infants (aged 6 months to 5 years old) and the elderly (aged 60-80 years old) for the seasonal prevention of Respiratory Syncytial…
- Trial name
- NCT04681833
- Testing
- Recombinant Respiratory Syncytial Virus Vaccine (BARS13)
- Where
- 2 sites in Australia
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.